A multicenter clinical trial of piperacillin/tazobactam in burn infection.
- Author:
Weishi XU
1
;
Shilin DENG
;
Chunmao HAN
;
Xiaojian LI
;
Zhenjiang LIAO
;
Wenkui WANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Burns; complications; drug therapy; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; analogs & derivatives; therapeutic use; Piperacillin; therapeutic use; Sepsis; etiology; prevention & control; Treatment Outcome
- From: Chinese Journal of Burns 2002;18(2):75-77
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of piperacillin/tazobactam in the management of burn infection.
METHODSSixty-three burn patients were enrolled in the study with burn sepsis or burn area more than 50%TBSA or full skin loss more than 30% TBSA. The administration regime of the antibiotics was 4.5 g intravenously administered every 8 hours in the treatment of burn sepsis or in the prophylactic management. The effectiveness was identified when the septic symptoms disappeared or focal infection did not develop into sepsis.
RESULTSThe overall clinical efficacy was 90.4%, and success in sepsis (control) was 75%. Furthermore, 95.7% of the focal infection was prevented from developing into systemic infection. The bacterial clearance rates were 71.4% and 51.4% in treatment and prophylaxis groups, respectively.
CONCLUSIONPiperacillin/taxobactam was effective in the treatment and/or prophylaxis of burn sepsis caused by bacteria susceptible to it, so it could be applied empirically.
